HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel
Angelo Di Leo(Hospital of Prato), Denis Larsimont(Nottingham City Hospital), Virginie Durbecq, Matti Aapro(Clinique de Genolier), John Crown(St. Vincent's University Hospital), I. Bodrogi(Aarhus University Hospital), S Korec(Goethe University Frankfurt), Kay Friedrichs(Goethe University Frankfurt), Stephen Chan(Heidelberg University), Marianne Paesmans(Université Libre de Bruxelles), Elizabeth Murray(University College London), Jorma Isola(Tampere University Hospital), Peter Simmonds(University of Turku), Tamás Pintér(Goethe University Frankfurt), Euan Walpole(The University of Queensland), Martine Piccart(Université Libre de Bruxelles), Bernard Lespérance(Hôpital du Sacré-Cœur de Montréal), V. Cocquyt(Ghent University Hospital), Gϋnter von Minckwitz(German Breast group), Jean-Yves Leroy
Cited by 138
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k